SB
FPRX

Suntrust Banks’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

Suntrust Banks’s Portfolio FPRX Stock Details FPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-4,497
Closed -$225K – 1549
2016
Q4 		$225K Buy
4,497
+312
+7% +$16.4K ﹤0.01% 1413
2016
Q3 		$219K Buy
+4,185
New +$200K ﹤0.01% 1387

Other funds holding FPRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Suntrust Banks's FPRX Position: Q1 2017 in Review

Suntrust Banks sold out of Five Prime Therapeutics, Inc. (FPRX) in Q1 2017, closing a stake of 4,497 shares — an estimated $225K sold.

Suntrust Banks first reported a position in FPRX in Q3 2016 and held it in 2 quarters. The position peaked at $225K in Q4 2016. 157 funds tracked by Wall St. Rank hold FPRX as of Q1 2017.

  • Suntrust Banks reported no remaining Five Prime Therapeutics, Inc. position as of Q1 2017 after selling out during the quarter.
  • Suntrust Banks sold 4,497 Five Prime Therapeutics, Inc. shares in Q1 2017, an estimated $225K.
  • Suntrust Banks first reported a position in Five Prime Therapeutics, Inc. in Q3 2016 and held it in 2 quarters.
  • Suntrust Banks's Five Prime Therapeutics, Inc. position peaked at $225K in Q4 2016.
  • 157 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q1 2017.

Based on Suntrust Banks's 13F filing for Q1 2017, filed 3 May 2017.